13F Holdings
中文EN

CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1100682 · Fiscal year ends 12/27

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.2%
TTM net income YoY148.8%
TTM EPS YoY160.5%
Revenue 3-yr CAGR-1.9%
Net income 3-yr CAGR-56.1%

Margins

Gross margin—
Operating margin4.0%
Net margin1.0%
FCF margin10.0%
EBITDA margin11.2%

Returns

ROE1.2%
ROA0.5%
ROIC (approx.)2.3%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets56.0%
Debt / equity0.76x
Current ratio1.41x
Interest coverage1.45x

Cash quality & payout

Operating cash flow / net income15.49x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-27FY20242024-12-28FY20232023-12-30FY20222022-12-31FY20212021-12-25
Income statement
Revenue$4.02B$4.05B$4.13B$3.98B$3.54B
SG&A expense$743.07M$751.00M$747.86M$665.10M$619.92M
Operating income$25.16M$227.35M$617.26M$650.98M$589.86M
Interest expense$107.03M$126.29M$136.71M$59.29M$73.91M
Pretax income-$99.50M$93.11M$581.28M$622.99M$480.71M
Income tax$42.66M$67.82M$100.91M$130.38M$81.87M
Net income-$144.34M$22.20M$474.62M$486.23M$390.98M
EBITDA$428.47M$589.09M$931.38M$954.85M$855.40M
EPS (basic)-2.910.209.279.577.77
EPS (diluted)-2.910.209.229.487.60
Weighted avg. shares (diluted)49.56M51.63M51.45M51.30M51.42M
Banking
Provision for credit losses———$6.71M$1.66M
Balance sheet
Cash & equivalents$213.77M$205.57M$284.48M$241.21M$246.31M
Short-term investments————$1.06M
Receivables$708.86M$720.91M$780.38M$752.39M$642.88M
Inventory$299.10M$278.54M$380.26M$255.81M$199.15M
Current assets$1.45B$1.40B$1.61B$1.44B$1.27B
PP&E, net$1.66B$1.60B$1.64B$1.47B$1.29B
Goodwill$2.76B$2.85B$3.10B$2.85B$2.71B
Intangibles$340.00M$723.40M$864.05M$955.27M$1.06B
Total assets$7.14B$7.53B$8.20B$7.60B$7.02B
Current liabilities$1.12B$994.10M$1.06B$1.09B$1.03B
Short-term debt$166,000$155,000$3.17M$1.35M$101,000
Long-term debt$2.14B$2.24B$2.65B$2.71B$2.66B
Total debt$2.14B$2.24B$2.65B$2.71B$2.66B
Total liabilities$3.92B$4.02B$4.54B$4.58B$4.43B
Shareholders' equity$3.16B$3.46B$3.60B$2.98B$2.53B
Net debt$1.92B$2.03B$2.37B$2.47B$2.42B
Shares outstanding49.22M51.14M51.34M50.94M50.48M
Cash flow statement
Operating cash flow$737.65M$734.58M$683.90M$619.64M$760.80M
Capital expenditure$219.15M$232.97M$318.53M$324.73M$228.77M
Free cash flow$518.49M$501.61M$365.37M$294.91M$532.03M
Investing cash flow-$209.32M-$245.09M-$563.15M-$607.92M-$1.44B
Financing cash flow-$536.73M-$550.93M-$85.52M-$42.40M$672.60M
Depreciation & amortization$403.31M$361.74M$314.12M$303.87M$265.54M
Stock-based compensation$71.08M$69.89M$72.05M$73.62M$71.47M
Share buybacks$360.67M$119.17M$24.16M$38.65M$40.71M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.